The NHS is offering autumn Covid boosters to the most vulnerable in October. Many pharmacies also now sell the Covid jab ...

When “the Greater Good” Matters The business pages, and now the mainstream media, have been dominated over the last week with news of Pfizer’s proposed $106bn takeover of AstraZeneca, which would make ...

AZN's Daiichi Sankyo-partnered datopotamab deruxtecan fails to show overall survival benefits in a breast cancer study. Stock ...

AstraZeneca is continuing to study AZD8205 as a monotherapy in dose optimization expansion cohorts of patients with ...

Pfizer chief executive Ian Read is to go head-to-head with AstraZeneca's Pascal Soriot in two parliamentary hearings to argue for the future of the UK-based company. The two CEOs have been called ...

Responding to rising mpox cases in Africa, the World Health Organization declared a public health emergency of international ...

Pfizer has made a new and improved bid to acquire AstraZeneca with an offer worth £69.3 billion pounds ($116.6 billion) or £55 a share – and says this is its best and final offer for the firm.

Patients with HER2-positive advanced or metastatic breast cancer received trastuzumab deruxtecan every 3 weeks.

This summary covers various health news: a Nipah virus death in Kerala, Gaza's polio vaccination coverage success, brain ...